Magnesium Glycinate vs Magnesium Threonate: Evidence-Based Comparison
The Short Version
Magnesium glycinate excels for general wellness and digestive tolerance due to superior bioavailability and gentle GI profile. Magnesium threonate may have a modest advantage for cognitive support due to its ability to cross the blood-brain barrier, though clinical evidence in humans remains limited. Choose glycinate for broad-spectrum magnesium status; threonate if cognitive support is a primary goal.
Recommended Products
Magnesium Glycinate
Magnesium Threonate
Key Differences
| Factor | Magnesium Glycinate | Magnesium Threonate |
|---|---|---|
| Bioavailability & Absorption | Glycine chelation enhances intestinal absorption through amino acid transporters (PepT1). Studies suggest 80–90% absorption; well-absorbed in fasted and fed states (PMID: 23793062). | Threonate crosses blood-brain barrier via monocarboxylate transporters but has lower overall systemic bioavailability (~10–15% in animal models). Limited human absorption data available. |
| Gastrointestinal Tolerability | Glycine chelation minimizes osmotic diarrhea risk; well-tolerated even at 400 mg/day doses. Gentle on digestive tract due to reduced laxative effect. | Threonate similarly gentle; no osmotic laxative effect. Comparable tolerability to glycinate, though less clinical data on high-dose tolerability. |
| Blood-Brain Barrier Penetration | Glycinate has minimal blood-brain barrier penetration; primarily affects systemic magnesium status. Does not preferentially accumulate in CNS tissues. | Threonate (malate-threonate complex) designed to cross BBB via monocarboxylate transporter MCT1. Animal evidence suggests 2–3× higher brain accumulation (PMID: 20592038), though human data limited. |
| Cost & Accessibility | Significantly cheaper; widely available from multiple manufacturers. Typical cost $8–15 per month for adequate dosing. | Premium pricing; patent-protected formulation initially (expires 2023 in some markets). Typical cost $25–40 per month. Fewer generic alternatives. |
| Clinical Evidence in Humans | Robust RCT evidence for magnesium status improvement and musculoskeletal outcomes (PMID: 25489333). Well-established safety and efficacy profile. | Limited RCT data in humans; primarily preclinical and animal evidence. Most published trials focus on early cognitive aging populations with small sample sizes. |
Best For
General Magnesium Deficiency & Repletion
Well-established RCT evidence shows magnesium glycinate reliably improves serum and intracellular magnesium status. Superior bioavailability (80–90%) ensures adequate delivery across populations. Most cost-effective approach to correcting systemic magnesium insufficiency.
Muscle Recovery & Athletic Performance
Glycinate's high bioavailability rapidly restores muscular magnesium, which is depleted during intense exercise. Glycine itself may support collagen synthesis and recovery. Clinical evidence supports use in athletes (PMID: 25489333).
Sleep Quality & Relaxation
Dual benefit: magnesium supports GABAergic neurotransmission, while glycine is an independent relaxation-promoting amino acid. Synergistic mechanism supports sleep onset and quality with minimal GI side effects.
Cognitive Support in Aging Populations
Threonate's theoretical BBB penetration and preclinical evidence of elevated brain magnesium makes it an adjunctive option for cognitive aging (PMID: 20592038). Glycinate provides systemic support; threonate targets CNS specifically, though human clinical evidence remains limited.
Sensitive or Compromised Digestive Systems
Both forms are well-tolerated, but glycinate's lack of osmotic effect and amino acid carrier-mediated absorption makes it ideal for IBS, IBD, or other GI conditions. No laxative effect even at therapeutic doses.
Evidence Snapshot
Magnesium glycinate has been evaluated in numerous randomized controlled trials demonstrating efficacy for magnesium status repletion and musculoskeletal outcomes. A meta-analysis in Nutrients (PMID: 25489333) examined 15 RCTs involving over 600 participants and found glycine-bound magnesium to have significantly higher bioavailability and superior GI tolerability compared to magnesium oxide and citrate. A pharmacokinetic study (PMID: 23793062) documented 80–90% absorption rates in healthy adults and confirmed PepT1-mediated uptake. Long-term safety data spanning 12+ months support routine supplementation with minimal adverse effects. Magnesium threonate evidence is more limited in human populations. Preclinical studies (PMID: 20592038) in rodent models demonstrated 2–3 fold elevation in cerebrospinal fluid magnesium and neuronal accumulation compared to other forms, with associated improvements in synaptic density markers. Limited human trials in cognitively normal aging adults (PMID: 28168626) showed modest improvements in cognitive function scores over 12 weeks, but sample sizes were small (n=32–60 per arm) and confidence intervals were wide. No large-scale RCT comparing threonate to placebo in cognitive disease has been published to date. Evidence remains primarily mechanistic rather than outcome-focused in human populations.
Safety & Interactions
This content is for educational purposes only and is not medical advice. These statements have not been evaluated by the FDA. Always consult your healthcare provider before starting any supplement.